Outlook Therapeutics Files 8-K on Financials
Ticker: OTLK · Form: 8-K · Filed: Dec 27, 2024 · CIK: 1649989
| Field | Detail |
|---|---|
| Company | Outlook Therapeutics, Inc. (OTLK) |
| Form Type | 8-K |
| Filed Date | Dec 27, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
TL;DR
Outlook Therapeutics dropped an 8-K detailing their financials. Check it out.
AI Summary
Outlook Therapeutics, Inc. filed an 8-K on December 27, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located in Iselin, New Jersey.
Why It Matters
This filing provides investors with crucial updates on Outlook Therapeutics' financial performance and operational status, which can influence investment decisions.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can significantly impact a company's stock price, requiring careful investor attention.
Key Players & Entities
- Outlook Therapeutics, Inc. (company) — Registrant
- December 27, 2024 (date) — Date of earliest event reported
- Iselin, New Jersey (location) — Address of principal executive offices
- 001-37759 (company) — Commission File Number
FAQ
What specific financial results are being reported in this 8-K filing?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific details of these results are not provided in the provided text.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on December 27, 2024.
What is the primary business of Outlook Therapeutics, Inc.?
Outlook Therapeutics, Inc. is in the 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' industry, SIC code 2836.
Where are Outlook Therapeutics, Inc.'s principal executive offices located?
The principal executive offices of Outlook Therapeutics, Inc. are located at 111 S. Wood Avenue, Unit #100, Iselin, New Jersey 08830.
Has Outlook Therapeutics, Inc. had a former company name or address?
Yes, the company was formerly known as Oncobiologics, Inc., with a date of name change on August 4, 2015.
Filing Stats: 503 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-12-27 08:14:56
Filing Documents
- tm2431904d1_8k.htm (8-K) — 24KB
- tm2431904d1_ex99-1.htm (EX-99.1) — 46KB
- tm24319041d1_ex99-1img001.jpg (GRAPHIC) — 5KB
- 0001104659-24-131957.txt ( ) — 254KB
- otlk-20241227.xsd (EX-101.SCH) — 3KB
- otlk-20241227_lab.xml (EX-101.LAB) — 33KB
- otlk-20241227_pre.xml (EX-101.PRE) — 22KB
- tm2431904d1_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition On December 27, 2024, Outlook Therapeutics, Inc. issued a press release announcing its financial results for its fourth fiscal quarter and year ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Exhibit No . Description 99.1 Press Release dated December 27, 2024. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Outlook Therapeutics, Inc. Date: December 27, 2024 By: /s/ Lawrence A. Kenyon Lawrence A. Kenyon Chief Financial Officer